Business UpdateJun 23, 2026, 04:43 PM
Silence Therapeutics Updates Corporate Presentation with Pipeline Progress
AI Summary
Silence Therapeutics plc announced the issuance of an updated corporate presentation, reflecting recent business developments and pipeline advancements. The presentation highlights significant progress across its siRNA therapeutic programs, including anticipated Phase 2 topline results for Divesiran in Polycythemia Vera in Q3 2026. Additionally, the company is set to regain global rights to SLN312 for dyslipidemia and is advancing preclinical programs for SLN365 and SLN098 with potential IND filings targeted for 2027.
Key Highlights
- Silence Therapeutics issued an updated corporate presentation detailing pipeline progress and upcoming milestones.
- Topline results for the SANRECO Phase 2 study of Divesiran for Polycythemia Vera are expected in Q3 2026.
- Silence Therapeutics will regain exclusive global rights to SLN312 for dyslipidemia following Phase 1 completion by AstraZeneca.
- Preclinical data for SLN365 (HoFH) showed over 80% mRNA knockdown in non-human primates, with a potential IND filing in H2 2027.
- Preclinical data for SLN098 (Obesity) demonstrated approximately 90% protein knockdown in NHPs, with a potential IND filing by year-end 2027.
Price Impact
More from SLN